Left Ventricular Dysfunction
Cardiac dysfunction from cancer therapies increases risk for pregnancy-related HF
Women who had a history of cardiac dysfunction related to cancer therapeutics had a 47.4-fold increased risk for HF or left ventricular dysfunction during pregnancy or within 12 months after delivery, according to a systematic review.
COVID-19 may impair certain kinds of ventricular function
Patients with COVID-19 had impaired left ventricular diastolic and right ventricular function despite most patients having preserved LV systolic function, researchers found in a study published in Circulation.
Immune globulin treatment recovers LV systolic function in children with COVID-19
Treatment with immune globulin led to left ventricular systolic function recovery in children with acute cardiac decompensation from inflammation associated with COVID-19, according to a study published in Circulation.
Dexrazoxane preserves cardiac function without compromising survival in pediatric AML
Dexrazoxane appeared to preserve cardiac function without compromising EFS and OS among pediatric patients undergoing chemotherapy for acute myeloid leukemia, according to results of a prospective study published in Journal of Clinical Oncology.
In PCI for ACS, elevated LV end-diastolic pressure may confer mortality risk
Among patients undergoing PCI for ACS, elevated left ventricular end-diastolic pressure was associated with a significant increase in risk for all-cause mortality.
Top news in cardiac technology: Remote monitoring, Apple Heart Study and more
Healio and Cardiology Today present the top stories in cardiac technology. Our readers were most interested in remote monitoring, implantable LVADs and the latest research from the Apple Heart Study.
DAPA-HF
Researchers compared outcomes of dapagliflozin (Farxiga, AstraZeneca) vs. placebo in patients with HF with reduced ejection fraction with or without diabetes.
FDA approves sacubitril/valsartan for pediatric HF
Novartis announced that sacubitril/valsartan has been approved by the FDA for the treatment of children aged 1 year and older with symptomatic HF and systemic left ventricular systolic dysfunction.
Debate: LVEF significance or lack thereof in HF decision-making
PHILADELPHIA — The consideration of left ventricular ejection fraction when diagnosing or making treatment decisions for HF was a topic for debate at the Heart Failure Society of America Scientific Meeting.
Novel percutaneous LV repair system shows promise in systolic HF
SAN FRANCISCO — Early clinical data suggest that an investigational percutaneous device designed to directly repair the left ventricle is feasible and safe in patients with HF and functional mitral regurgitation. Data on the first 31 patients enrolled in the CorCinch FMR early feasibility study who were treated with the AccuCinch ventricular repair system at U.S. centers through July were presented at TCT 2019.